Reversing poor graft function with eltrombopag after allogeneIc hematopoietic cell transplantation : a prospective, phase II study by the SFGM-TC
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Eltrombopag (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- Acronyms REGALIA
- 03 Dec 2019 Planned End Date changed from 1 Jan 2021 to 1 Dec 2021.
- 03 Dec 2019 Planned primary completion date changed from 1 Jan 2021 to 1 Dec 2021.
- 03 Dec 2019 Status changed from not yet recruiting to recruiting.